Compare CNVS & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNVS | MIRA |
|---|---|---|
| Founded | 2000 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.5M | 43.7M |
| IPO Year | 2016 | 2023 |
| Metric | CNVS | MIRA |
|---|---|---|
| Price | $2.47 | $1.04 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 145.8K | 127.7K |
| Earning Date | 02-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.99 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $78,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $84.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 59.13 | N/A |
| 52 Week Low | $1.77 | $0.90 |
| 52 Week High | $7.39 | $2.45 |
| Indicator | CNVS | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.42 | 45.10 |
| Support Level | $2.31 | $0.99 |
| Resistance Level | $2.56 | $1.24 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 52.81 | 17.86 |
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.